Medications for Choroidal Neovascularization
3 results
Byooviz (ranibizumab-nuna)
(ranibizumab-nuna)BIOGEN INC.
Usage: BYOOVIZ is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).
Cimerli (ranibizumab-eqrn)
(ranibizumab-eqrn)Coherus BioSciences Inc
Usage: CIMERLI is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
Lucentis (ranibizumab)
(RANIBIZUMAB)Genentech, Inc.
Usage: LUCENTIS is indicated for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).